ENvue Medical, Inc. 8-K

What Happened
ENvue Medical, Inc. (FEED) filed an 8-K on July 10, 2026, reporting that Nasdaq’s Listing Qualifications Staff determined the company’s closing bid price was below the $1.00 minimum for 30 consecutive business days (May 26, 2026–July 8, 2026), putting the company out of compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq also determined ENvue is not eligible for the usual 180-calendar day compliance period under Rule 5810(c)(3)(A) because the company completed a 1-for-10 reverse stock split on August 12, 2025 (Rule 5810(c)(3)(A)(iv)). ENvue intends to request a hearing before Nasdaq’s Hearings Panel to appeal the Staff’s determination; a timely hearing request will stay any suspension or delisting pending the Panel’s decision.

Key Details

• Nasdaq found ENvue out of compliance for the 30 consecutive business days ending July 8, 2026 (May 26–July 8, 2026).
• The company completed a 1-for-10 reverse stock split on August 12, 2025, which makes it ineligible for the standard 180-day compliance period.
• ENvue will request a hearing before the Nasdaq Hearings Panel; a timely request stays delisting or suspension while the appeal is decided.
• The filing includes customary forward-looking statements about the outcome and risks of the appeal.

Why It Matters
This notice signals a material listing risk: if the Panel denies ENvue’s request for continued listing or the company fails to regain the $1 minimum bid price, Nasdaq could suspend trading or delist the stock. Delisting (or prolonged non-compliance) can reduce liquidity, limit investor access, and affect institutional ownership. The company’s appeal preserves its listing status for now, but there is no assurance the appeal will be successful. Retail investors should be aware of the elevated listing risk and watch future updates and trading developments.